About: Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus (SARS-CoV-2)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus (SARS-CoV-2) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus (SARS-CoV-2)
Creator	Feng, Ye Liu, Liang Qiu, Min Mo, Fan Li, Yun Han, Ning Zhang, Shanshan Chen, Shuqing Luo, Kai Qianpeng, Sun, Yingqiang Wang, Kui Zhuang, Xinlei Zou, Shengmei
Source	BioRxiv; MedRxiv
abstract	A new coronavirus SARS-CoV-2 has caused over 9.2 million infection cases and 475758 deaths worldwide. Due to the rapid dissemination and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2. An in silico approach based on the available virus genome was applied to identify 19 high immunogenic B-cell epitopes and 499 human-leukocyte-antigen (HLA) restricted T-cell epitopes. Thirty multi-epitope peptide vaccines were designed by iNeo Suite, and manufactured by solid-phase synthesis. Docking analysis showed stable hydrogen bonds of epitopes with their corresponding HLA alleles. When four vaccine peptide candidates from the spike protein of SARS-CoV-2 were selected to immunize mice, a significantly larger amount of IgG in serum as well as an increase of CD19+ cells in ILNs was observed in peptide-immunized mice compared to the control mice. The ratio of IFN-γ-secreting lymphocytes in CD4+ or CD8+ cells in the peptides-immunized mice were higher than that in the control mice. There were also a larger number of IFN-γ-secreting T cells in spleen in the peptides-immunized mice. This study screened antigenic B-cell and T-cell epitopes in all encoded proteins of SARS-CoV-2, and further designed multi-epitope based peptide vaccine against viral structural proteins. The obtained vaccine peptides successfully elicited specific humoral and cellular immune responses in mice. Primate experiments and clinical trial are urgently required to validate the efficacy and safety of these vaccine peptides. Importance So far, a new coronavirus SARS-CoV-2 has caused over 9.2 million infection cases and 475758 deaths worldwide. Due to the rapid dissemination and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2. Different from the development approaches for traditional vaccines, the development of our peptide vaccine is faster and simpler. In this study, we performed an in silico approach to identify the antigenic B-cell epitopes and human-leukocyte-antigen (HLA) restricted T-cell epitopes, and designed a panel of multi-epitope peptide vaccines. The resulting SARS-CoV-2 multi-epitope peptide vaccine could elicit specific humoral and cellular immune responses in mice efficiently, displaying its great potential in our fight of COVID-19.
has issue date	2020-06-30(xsd:dateTime)
bibo:doi	10.1101/2020.03.03.962332
has license	biorxiv
sha1sum (hex)	202383e9c79c6dac9c6de7622681a2b2fdd699b6
schema:url	https://doi.org/10.1101/2020.03.03.962332
resource representing a document's title	Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus (SARS-CoV-2)
schema:publication	bioRxiv
resource representing a document's body	covid:202383e9c79c6dac9c6de7622681a2b2fdd699b6#body_text
is schema:about of	named entity 'study' named entity 'vaccines' named entity 'genome' named entity 'virus' named entity 'immune' named entity 'cellular' named entity 'specific' named entity 'T cells' named entity 'validate' named entity 'worldwide' named entity 'PEPTIDE' named entity 'HIGHER' named entity 'SELECTED' named entity '499' named entity 'B-CELL' named entity 'LARGER' named entity '9.2' named entity 'mice' named entity 'coronavirus' named entity 'epitopes' named entity 'vaccine' named entity 'peptide' named entity 'B-cell' named entity 'SARS-CoV-2' named entity 'When' named entity 'mice' named entity 'serum' named entity 'human-leukocyte-antigen' named entity 'immunogenic' named entity 'epitopes' named entity 'peptides' named entity 'lymphocytes' named entity 'spike protein' named entity 'mice' named entity 'infection' named entity 'coronavirus' named entity 'T-cell' named entity 'clinical trial' named entity 'mice' named entity 'cells' named entity 'epidemic' named entity 'rapid' named entity 'ELISA assay' named entity 'T-cell' named entity 'antibody' named entity 'epitopes' named entity 'flow cytometry' named entity 'neutralizing antibody' named entity 'vaccine' named entity 'peptides' named entity 'epitopes' named entity 'pymol' named entity 'peptides' named entity 'HLA' named entity 'HLA' named entity 'mutation' named entity 'peptides' named entity 'protein' named entity 'lymphocytes' named entity 'alleles' named entity 'HLA' named entity 'SARS-CoV-2' named entity 'Amino acids' named entity 'T-cell' named entity 'mice' named entity 'randomly selected' named entity 'epitope' named entity 'epitopes' named entity 'HLA' named entity 'alleles' named entity 'peptides'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software